This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (19)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

An Evaluation of Treatment with Disodium Edetate

KENNETH H. NELDNER, M.D.; R. K. WINKELMANN, M.D.; HAROLD O. PERRY, M.D.

Arch Dermatol. 1962;86(3):305-309.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In recent years a new chelating agent, disodium edetate, the disodium salt of ethylenediaminetetraacetic acid (Versenate, Endrate) was proposed for the treatment of scleroderma. It was first used for scleroderma by Klein and Harris¹ in 1955. They reported a favorable response in a single patient with systemic scleroderma and calcinosis cutis. It was postulated that the ability of edetate to combine with calcium explained its mechanism of action. Subsequent studies² have shown that although a temporary increase in excretion of urinary calcium does occur and that hypocalcemic tetany can result from too rapid administration of the drug, the effect is of only short duration and probably occurs only while the drug is being given. A more current concept is that edetate produces a "trace-metal effect," presumably involving cofactors of enzyme systems.

Chelation refers to the ability of certain chemicals to combine selectively with metallic ions and incorporate them . . . [Full Text PDF of this Article]

Author Affiliations
ROCHESTER, MINN.

Fellow in Dermatology (Dr. Neldner), Section of Dermatology (Dr. Winkelmann, Dr. Perry), Mayo Clinic and Mayo Foundation.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?